Maximum chest CT score is associated with progression to severe illness in patients with COVID-19: A retrospective study from Wuhan, China

Jianwei Xiao
The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology

Xiang Li
The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology

Yuanliang Xie
The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology

Zengfa Huang
The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology

Yi Ding
The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology

Shengchao Zhao
The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology

Pei Yang
The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology

Dan Du
The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology

Bin Liu
The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology

xiang wang (wangxiangwhch1971@163.com)
The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology

https://orcid.org/0000-0002-0105-9755

Research article

Keywords: Chest CT, COVID-19, COPD, ROC, CT score, multivariate regression

DOI: https://doi.org/10.21203/rs.3.rs-51054/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: The Coronavirus Disease 2019 (COVID-19) pandemic is a world-wide health crisis. Limited information is available regarding which patients will experience more severe disease symptoms. We evaluated hospitalized patients who were initially diagnosed with moderate COVID-19 for clinical parameters and radiological feature that showed an association with progression to severe/critical symptoms.

Methods: This study, a retrospective single-center study at the Central Hospital of Wuhan, enrolled 243 patients with confirmed COVID19 pneumonia. Forty of these patients progressed from moderate to severe/critical symptoms during follow up. Demographic, clinical, laboratory, and radiological data were extracted from electronic medical records and compared between moderate- and severe/critical-type symptoms. Univariable and multivariable logistic regressions were used to identify the risk factors associated with symptom progression.

Results: Patients with severe/critical symptoms were older (p<0.001) and more often male (p=0.046). A combination of chronic obstructive pulmonary disease (COPD) and high maximum chest computed tomography (CT) score was associated with disease progression. Maximum CT score (>11) had the greatest predictive value for disease progression. The area under the receiver operating characteristic curve was 0.861 (95% confidence interval: 0.811-0.902).

Conclusions: Maximum CT score and COPD were associated with patient deterioration. Maximum CT score (>11) was associated with severe illness.

Background

Worldwide, the Coronavirus Disease 2019 (COVID-19) pandemic, caused by infection with the novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2), has resulted (as of October 23, 2020) in 41,570,883 confirmed cases and 1,134,940 deaths [1]. As of that date, the rate of overall case-fatality across China was approximately 5.1%. Although relatively few deaths have been observed in patients with mild COVID-19, the rate of case fatality clearly is elevated among critically ill patients. Nevertheless, the nature of the factors influencing the prognosis of COVID-19 patients remains unclear [2, 3].

The onset of COVID-19 is associated with symptoms such as fever, cough, and myalgia. The case definition adopted in China and elsewhere includes further stratification of cases as mild, moderate, and severe/critical [4]. More than 80% of the laboratory-confirmed cases in China (including both non-pneumonia and pneumonia cases) were of the mild to moderate types [5]. A fifth of these cases progressed to a severe or critical stage, with the highest reported case fatality rate reaching 4.47% for patients in Wuhan diagnosed before March 2020 [6]. Most previous studies have focused only on the general epidemiological findings, clinical characteristics, and outcomes of patients with COVID-19 [3, 7, 8]. However, few studies (to our knowledge) have investigated clinical findings in patients who progress from moderate- to severe/critical-type symptoms.
In this study, we performed a comprehensive analysis of the clinical course and imaging findings of 243 hospitalized COVID-19 patients who initially presented with moderate-type symptoms. These patients were admitted to the isolation ward of the Central Hospital of Wuhan; this facility was one of the first hospitals in Wuhan to admit COVID-19 patients, and is located very close to a seafood market suspected as a source of the initial outbreak. We sought to identify risk factors associated with progression from moderate- to severe/critical-type symptoms in COVID-19 patients.

**Methods**

**Study design and participants**

This research consisted of a retrospective single-center study at the Central Hospital of Wuhan. The study was approved (Approval No. 2020421) by the Central Hospital of Wuhan Ethics Committee; the requirement for written informed consent was waived by the Ethics Commission of the designated hospital based on the exigencies associated with emerging infectious diseases.

This study consecutively enrolled all patients at the Central Hospital of Wuhan who were diagnosed with COVID-19, based on WHO interim guidelines, between December 25, 2019, to February 16, 2020 [9]. The study design protocol was finalized before the initiation of data collection. Based on the new coronavirus pneumonia diagnosis and treatment protocols (version 6) developed by the National Health Commission of the People's Republic of China (http://www.nhc.gov.cn/), the clinical classification of COVID-19 was stratified as follows: moderate-type cases included individuals with fever, respiratory tract involvement, and other symptoms, as well as imaging findings of pneumonia; severe-type cases additionally met any of the following criteria: (1) respiratory distress with a respiratory rate $\geq 30$ beats/min; (2) oxygen saturation $\leq 93\%$ at rest; and (3) arterial blood oxygen partial pressure (PaO$_2$)/oxygen concentration (FiO$_2$) $\leq 300$ mmHg (1 mmHg = 0.133 kPa); critical-type cases additionally exhibited any of the following conditions: (1) respiratory failure requiring mechanical ventilation; (2) shock; (3) intensive care unit (ICU) admission for combined organ failure.

**Inclusion and exclusion criteria**

Inclusion criteria were as follows: (1) diagnosis of COVID-19 based on exposure history or based on clinically compatible symptoms; (2) classification on admission as moderate type, according to protocols (version 6) developed by the National Health Commission of the People's Republic of China; and (3) recovery during the study period. Exclusion criteria were as follows: (1) patient was still hospitalized at the end of follow-up; (2) patient transferred to another medical institution; (3) diagnosis not confirmed by repeated tests for the presence of SARS-CoV-2 RNA; (4) fatality; (5) patient diagnosed with severe-type or critical-type COVID-19 on admission; (6) incomplete medical records; or (7) case records lacked a second chest computed tomography (CT) scan.

**Data collection**
Epidemiological, clinical, laboratory, and radiological characteristics, as well as outcome data, were extracted from electronic medical records. The data were reviewed by two physicians, and a third physician adjudicated any differences in interpretation between the two primary researchers. Fever was defined as axillary temperature higher than 37.3 °C. Epidemiological, clinical, and laboratory data were defined as the results of the first consultation or examination in the electronic medical records. The initial chest CT was defined as the first chest CT examination at or following admission.

**CT acquisition and evaluation**

Chest CT scans were performed with the patient in a supine position and using a single inspiratory phase on one of the four CT systems available at our facility. These machines included the following equipment: Bright Speed Elite (GE, America); Philips Ingenuity Core128 (Philips Medical Systems, Best, the Netherlands); uCT 760 (United Imaging, China); and SOMATOM Definition AS (Siemens Healthineers, Germany). The following primary settings were used: tube voltage, 120 kVp; automatic tube current modulation (20-130 mAs); matrix, 512×512; field of view (FOV), 350 mm × 350 mm - 370 mm × 370 mm; pitch, 0.75-1.25 mm; and slice thickness, 1-1.5 mm. The reconstructed images were sent automatically to the corresponding post-processing workstation and Picture Archiving and Communication Systems (PACS) for multiplanar reconstruction post-processing. All chest CT images were analyzed independently, and the features were scored by a senior thoracic radiologist with more than 20 years of experience who was blinded to clinical and laboratory findings. A previously described semi-quantitative scoring system was used to estimate the pulmonary involvement of lesions on the basis of the area involved [10]. Briefly, each of the 5 lung lobes was visually scored from 0 to 5, as follows: 0, no involvement; 1, <5% area involvement; 2, 5%-25% area involvement; 3, 26%-49% area involvement; 4, 50%-75% area involvement; and 5, >75% area involvement. The total CT score was calculated as the sum of the scores for the 5 lung lobes in a given case, yielding a value that ranged from 0-25. All CT scans acquired after the development of severe disease were excluded.

**Endpoints**

After admission, patients were subjected to re-examination by performing a second chest CT scan. Serial chest CT scans were performed based on the hospital’s clinical decision policy. The primary endpoint of the present study was the development of severe/critical illness. The secondary endpoint was recovery from COVID-19.

**Statistical analyses**

Continuous variables are presented as mean ± SD or median with interquartile range (IQR), depending on the normality of distribution. Categorical variables are presented as frequencies and percentages. Continuous variables were compared between the moderate-type group and the severe/critical-type group using a non-paired Student’s t-test or Mann-Whitney U test. Categorical variables were compared using a chi-squared test or Fisher’s exact test, as appropriate. Univariable and multivariable logistic regression models were used to explore the risk factors associated with progression from moderate-type symptoms.
to severe/critical-type symptoms. Considering the total number of severe/critical-type cases (n=40) in the present study, and to avoid overfitting in the model, we excluded variables if any of the following conditions applied: between-group differences in variables were not significant; variable accuracy was unconfirmed (e.g., surgery history, which was self-reported); number of events was too small to calculate an odds ratio; or variables exhibited collinearity with the maximum CT score. Using the new coronavirus pneumonia diagnosis protocols as the standard of reference, diagnostic performance with the highest CT score of cases that progressed to severe/critical type was determined using analyses of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), accuracy, and area under the curve (AUC). The 95% confidence intervals (CIs) also were reported. Diagnostic ability was illustrated using a receiver operating characteristic curve (ROC). A two-tailed \( p < 0.05 \) was considered statistically significant. All statistical analyses were performed using SPSS, version 18 (SPSS, Inc., Chicago, IL).

**Results**

A total of 457 adult patients diagnosed with COVID-19 were admitted to our hospital from December 25, 2019, to February 16, 2020. Of these, 191 patients remained hospitalized, had diagnoses that were not confirmed by SARS-CoV-2 RNA detection, or had died by the time of our final follow-up; these cases were excluded from our analysis. We also excluded another 7 patients who were diagnosed with severe/critical-type symptoms on admission. An additional 16 patients were excluded because their medical records were not available. In total, 243 patients with confirmed COVID-19 pneumonia were enrolled in the analysis (Figure 1). Forty patients progressed from having moderate symptoms to severe/critical symptoms during follow-up. The mean age of these 243 patients was 47 years, with a range of 20 to 89 years. One hundred thirty-eight (56.8%) were female (Table 1). The patients who developed severe/critical symptoms were older (\( p < 0.001 \)) and more likely male (\( p=0.046 \)) than patients with moderate-type symptoms. The most common symptoms at onset were fever (83.5%) and cough (63.8%), followed by weakness (45.7%) and sputum (28.8%). Chest tightness was more likely to occur in patients with severe/critical symptoms (42.5%) than in patients with (\( p=0.002 \)). Patients in the severe/critical-type symptom group had (compared to patients in the moderate-type group) significantly higher mean serum levels of D-dimer (2.1±4 vs. 0.8±1.6 mg/L; \( p < 0.001 \)), C-reactive protein (3.6±3.2 vs. 2±3 mg/L; \( p=0.038 \)), α-hydroxybutyrate dehydrogenase (247±352 vs. 142±57 U/L; \( p < 0.001 \)), lactate dehydrogenase (251±119 vs. 185±79 U/L; \( p=0.002 \)), creatine kinase (273±636 vs. 120±172 U/L; \( p < 0.001 \)), and creatinine (211±449 vs. 67±43 μmol/L; \( p < 0.001 \)). The neutrophil-to-lymphocyte ratio (NLR) also was significantly higher in the severe/critical-type group than in the moderate-type group (10.6±7.7 vs 3.7±3.9; \( p < 0.001 \)). Other laboratory findings did not differ significantly between the two groups. In comparison to patients in the moderate-type group, patients in the severe/critical-type group were more likely to have underlying hypertension (15, 37.5% vs. 30, 14.8%, respectively), chronic obstructive pulmonary disease (COPD) (5, 12.5% vs. 5, 2.5%), and chronic kidney disease (6, 15% vs. 4, 2%).

All patients had abnormal CT imaging features (Figure 2). There were no significant differences in the initial CT scores between the moderate-type group and severe/critical-type group (\( p=0.112 \)). Compared to the moderate-type group, patients in the severe/critical-type group had significantly higher median
maximum CT score (7, IQR 0-20, vs. 14, IQR 3-28, respectively; \(p<0.001\)). There was no significant difference in the median time from onset of symptoms to hospitalization between the moderate-type group and the severe/critical-type group \((p=0.733\)). In comparison with patients in the moderate-type group, patients in the severe/critical-type group had longer hospital stays (22 days, IQR 18.5-28.5, vs. 18 days, IQR 13-24, respectively; \(p<0.001\)) and a longer time from illness onset to high CT score (13 days, IQR 8-17.8, vs. 9 days, IQR 6-12; \(p<0.001\)) (Figure 3).

Using univariable analysis, the calculated odds of progression to the severe/critical-type symptoms was found to be higher in patients having any comorbidity, including hypertension and COPD. Age (\(\geq 60\) years); sex (male); chest tightness; serum levels of D-dimer (\(\geq 1 \text{ mg/L}\)), C-reactive protein (\(\geq 1 \text{ mg/L}\)), \(\alpha\)-hydroxybutyrate dehydrogenase (\(\geq 180 \text{ U/L}\)), lactate dehydrogenase (\(\geq 250 \text{ U/L}\)), creatine kinase (\(\geq 190 \text{ U/L}\)), and creatinine (\(\geq 97 \mu\text{mol/L}\)); serum NLR; and highest CT score also were associated with disease progression. The length of the hospital stay and time from illness onset to the time of the highest CT score also were associated with disease progression. No collinearity was detected between variables. Next, we included these variables in the multivariable logistic regression analysis. We found that the combination of COPD (\(OR=9.06, 95\% \text{ CI} [1.30-63.36]; p=0.026\)) and a higher maximum CT score (\(OR=1.39, 95\% \text{ CI} [1.21-1.60]; p<0.001\)) were associated with disease progression (Table 2).

Using receiver operating characteristic curve (ROC) analysis, an optimal cutoff value of a maximum CT score of 11 with a sensitivity of 85.0\% (95\% CI: 70.2\%-94.3\%) and specificity of 78.3\% (95\% CI: 72\%-83.8\%) was shown to be predictive of disease progression (Figure 4). The area under the ROC was 0.861 (95\% CI: 0.811-0.902).

**Discussion**

This retrospective study identified high CT scores and COPD as risk factors for deterioration in hospitalized patients with COVID-19 in Wuhan, China. Additionally, being older and male, having chest tightness, hypertension, and elevated serum levels of D-dimer, C-reactive protein, \(\alpha\)-hydroxybutyrate dehydrogenase, lactate dehydrogenase, creatine kinase, creatinine, and serum NLR were associated with progression to severe or critical COVID-19 illness.

Recently, in a retrospective, multicenter cohort study of 191 patients, Zhou *et al.* demonstrated that older age is associated with mortality in hospitalized COVID-19 patients [11]. Other studies also have shown that older age (> 65 years) is associated with poorer clinical outcome in patients with COVID-19 [7, 12, 13]. The present study confirmed that more severely or critically ill patients were older (>60 years) than patients with moderate-type COVID-19 symptoms. An age-dependent risk also has been seen in previous studies of severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS) [13, 14]. However, in the current study, older age was not shown to be an independent predictor of deterioration in hospitalized patients with COVID-19. The difference between the present and previous studies may be due, in part, to the different outcomes being assessed. The current study was aimed at
the progress of moderate-type patients with COVID-19 who eventually recovered, rather than dying. Furthermore, we had a relatively small sample size for the severe/critical group.

Chest CT is the routine imaging modality for clinical diagnosis of patients with COVID-19 pneumonia in the Hubei Province. This technique may help in screening patients with suspected COVID-19 symptoms, especially those with a negative reverse transcription-polymerase chain reaction (RT-PCR) result at the early stages of the disease [15]. In order to comprehensively evaluate the CT features of COVID-19 pneumonia, a semi-quantitative scoring system has been developed to quantitatively estimate the severity of inflammation based on quantifying the extent of pulmonary abnormalities (including ground-glass opacities, consolidations, or other fuzzy interstitial opacities)[10]. Using this method, no significant difference in initial CT score was found between moderate-type and severe/critical-type groups in the present study. In contrast, a recent study showed that CT scores in severe/critical-type groups were significantly higher than those in the moderate-type groups [16]. This difference may reflect the fact that all of the patients with COVID-19 in the present study were of the moderate type initially. With the progression of COVID-19, there were significant differences in the highest CT scores between the moderate-type and severe/critical-type groups. Moreover, using multivariable analysis, the maximum CT score were found to be an important independent predictor of deterioration of patients who progressed from moderate-type symptoms to severe/critical-type symptoms. Furthermore, ROC analysis showed that an optimal cutoff value of a maximum CT score index of 11 (sensitivity of 85.0% and specificity of 78.3%) predicted deterioration. We hope that this maximum CT score index can be used to identify patients at earlier stages of COVID-19 who potentially may progress to severe/critical-type symptoms from moderate-type symptoms. Patients with this maximum CT score index then would receive more aggressive treatment and close monitoring. However, the efficacy of such an approach remains to be validated in multi-center and large-sample studies in the future.

Lung complications, especially pneumonia, are common in patients with COPD. According to a national cross-sectional study, the total number of patients with COPD in China approximates 100 million [17]. Most recent studies have shown no significant differences in COVID-19 severity between patients with and without COPD [2, 8, 18-20]. In the current study, COPD was more common in the severe/critical-type group than in the moderate-type group, a finding that agrees with the results reported by Guan et al. [7]. In addition, COPD was found (in the present study) to be associated with the deterioration of patients with COVID-19. It should be noted that all studies to date, including the present work, have used small sample sizes of COVID-19 patients with COPD. The potential impact of COPD on the disease outcomes of patients with COVID-19 requires further observation and research.

Comorbidities have been shown to be associated with an increase in the risk of developing severe COVID-19. Recently published data suggested that neither type 2 diabetes mellitus nor hypertension are associated with the risk of developing severe COVID-19 [21]. A high incidence of COVID-19 was reported among colorectal cancer subjects and lung cancer patients [22]. Malignancy also was associated with a higher risk of severe COVID-19 [22]. Separately, COVID-19 patients with underlying liver disease were observed to have worse outcomes [23]. However, these comorbidities did not show statistical
significance in our multivariable logistic regression analysis, presumably because of the relatively small sample size and few cases with complications.

Our study has some limitations. First, not all laboratory tests were done in all patients, including the measurement of levels of α-hydroxybutyrate dehydrogenase, lactate dehydrogenase, creatine kinase, procalcitonin and brain natriuretic peptide. Therefore, the roles of these parameters might be underestimated in predicting disease progression. In addition, we did not analyze the changes in laboratory findings in the process of the disease progression or patient recovery. Some of these results might also contribute to deterioration in some patients. Second, this was a retrospective study from a single center with a relatively small sample size and a certain selection bias, as some patients were transferred to other medical institutions by government decree. Thus, comparisons of clinical characteristics, laboratory findings, and imaging features may be skewed. In addition, chest CT score emerged as potentially associated with the risk for disease progression. However, there may have a risk of spurious association when multiple comparisons are made. Third, the semi-quantitative methods used for measuring COVID-19 pneumonia lesions may be somewhat subjective, and the time between the maximum chest CT score scan and the development of severe/critical illness was not analyzed as part of the present study. Last, infants, children and adolescents were not included in the present study; an effort should be made to include these groups in future studies.

Conclusions

Maximum CT score and COPD showed independent association with an increased risk of COVID-19 disease progression. A maximum CT score higher than 11 was associated with development of severe illness.

Abbreviations

COVID19: Coronavirus Disease 2019; CT: Computed Tomography; COPD: Chronic obstructive pulmonary disease; ROC: Receiver operating characteristic curve; NLR: Neutrophil Lymphocyte Ratio; IQR: Interquartile range; AUC: Area under the curve; CI: Confidence interval; PACS: Picture Archiving and Communication Systems; ICU: Intensive Care Unit.

Declarations

Ethics approval and consent to participate

The study was approved (Approval No. 2020421) by the Central Hospital of Wuhan Ethics Committee; the requirement for written informed consent was waived by the Ethics Commission of the designated hospital based on the exigencies associated with emerging infectious diseases.

Consent for publication
Not applicable.

**Availability of data and materials**

As the current manuscript describes the study protocol and no other data, we currently do not have any raw data to share.

**Conflict of interests**

The authors declare no conflict of interest.

**Funding**

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Authors’ contributions**

JWX and XW conceived and designed the study. YD, SCZ, PY, DD, and BL collected the data. JWX and XL wrote the paper. YLX and ZFH analyzed the data. XW reviewed and edited the manuscript. All authors read and approved the manuscript and agree to be accountable for all aspects of the research.

**Acknowledgments**

Not applicable.

**References**

1. Weekly update on COVID-19 - 23 October 2020, https://www.who.int/publications/m/item/weekly-update-on-covid-19—23-october.
2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X et al.: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020, 395(10223):497-506.
3. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y et al.: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020, 395(10223):507-513.
4. Yang G, Wang Y, Zeng Y, Gao GF, Liang X, Zhou M, Wan X, Yu S, Jiang Y, Naghavi M et al.: Rapid health transition in China, 1990-2010: findings from the Global Burden of Disease Study 2010. *Lancet* 2013, 381(9882):1987-2015.
5. Diseases NCfC: Report on cardiovascular diseases in China. 2014.
6. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, Ma K, Xu D, Yu H, Wang H et al.: Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ* 2020, 368:m1091.
7. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC et al.: Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 2020.

8. Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, Li SB, Wang HY, Zhang S, Gao HN et al.: Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. *BMJ* 2020, 368:m606.

9. DALYs GBD, Collaborators H: Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet* 2016, 388(10053):1603-1658.

10. Chang YC, Yu CJ, Chang SC, Galvin JR, Liu HM, Hsiao CH, Kuo PH, Chen KY, Franks TJ, Huang KM et al.: Pulmonary sequelae in convalescent patients after severe acute respiratory syndrome: evaluation with thin-section CT. *Radiology* 2005, 236(3):1067-1075.

11. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X et al.: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020, 395(10229):1054-1062.

12. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y et al.: Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020.

13. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M et al.: Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med* 2020.

14. Hong KH, Choi JP, Hong SH, Lee J, Kwon JS, Kim SM, Park SY, Rhee JY, Kim BN, Choi HJ et al.: Predictors of mortality in Middle East respiratory syndrome (MERS). *Thorax* 2018, 73(3):286-289.

15. Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J: Chest CT for Typical 2019-nCoV Pneumonia: Relationship to Negative RT-PCR Testing. *Radiology* 2020:200343.

16. Li K, Fang Y, Li W, Pan C, Qin P, Zhong Y, Liu X, Huang M, Liao Y, Li S: CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19). *Eur Radiol* 2020.

17. Wang C, Xu J, Yang L, Xu Y, Zhang X, Bai C, Kang J, Ran P, Shen H, Wen F et al.: Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. *Lancet* 2018, 391(10131):1706-1717.

18. Wang L, He W, Yu X, Hu D, Bao M, Liu H, Zhou J, Jiang H: Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up. *J Infect* 2020.

19. Liu W, Tao ZW, Lei W, Ming-Li Y, Kui L, Ling Z, Shuang W, Yan D, Jing L, Liu HG et al.: Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. *Chin Med J (Engl)* 2020.

20. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, Akdis CA, Gao YD: Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy* 2020.

21. Murillo-Zamora E, Trujillo X, Huerta M, Rios-Silva M, Mendoza-Cano O: Male gender and kidney illness are associated with an increased risk of severe laboratory-confirmed coronavirus disease.
22. Yarza R, Bover M, Paredes D, Lopez-Lopez F, Jara-Casas D, Castelo-Loureiro A, Baena J, Mazarico JM, Folgueira MD, Melendez-Carmona MA et al.: SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death. *European Journal of Cancer* 2020, 135:242-250.

23. Ji D, Xu J, Qin E, Zhang D, Cheng G, Wang Y, Lau G: Reply to: 'No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease'. *Journal of Hepatology* 2020, 73(3):718-719.

**Tables**
Table 1. Clinical characteristics, laboratory findings, and imaging features of 243 COVID-19 patients

| Characteristics | Total (n=243) | Moderate Type (n=203) | Severe/Critical Type (n=40) | p value |
|----------------|--------------|-----------------------|-----------------------------|---------|
| **Age, years** | 47.0 (20-89) | 44.7 (20-87)          | 58.7 (28-89)                | <0.001  |
| <60            | 175 (72)     | 154 (75.9)            | 21 (52.5)                   | 0.003   |
| ≥60            | 68 (28)      | 49 (24.1)             | 19 (47.5)                   |         |
| **Sex**        |              |                       |                             | 0.046   |
| Male           | 105 (43.2)   | 82 (40.4)             | 23 (57.5)                   |         |
| Female         | 138 (56.8)   | 121 (59.6)            | 17 (42.5)                   |         |
| **Symptoms**   |              |                       |                             |         |
| Fever          | 185 (83.5)   | 158 (77.8)            | 27 (67.5)                   | 0.161   |
| Cough          | 155 (63.8)   | 130 (64)              | 25 (62.5)                   | 0.853   |
| Sputum         | 70 (28.8)    | 56 (27.6)             | 14 (35)                     | 0.344   |
| Weakness       | 111 (45.7)   | 90 (44.3)             | 21 (54.5)                   | 0.343   |
| Diarrhea       | 21 (8.6)     | 18 (8.9)              | 3 (7.5)                     | 0.779   |
| Nausea/Vomiting| 20 (8.2)     | 14 (6.9)              | 6 (15)                      | 0.088   |
| Chest tightness| 57 (23.5)    | 40 (19.7)             | 17 (42.5)                   | 0.002   |
| Dyspnea        | 12 (4.9)     | 9 (4.4)               | 3 (7.5)                     | 0.413   |
| Condition                      | Count 1   | Count 2   | Count 3   | Count 4   |
|--------------------------------|-----------|-----------|-----------|-----------|
| Myalgia                        | 66 (27.2) | 58 (28.6) | 8 (20)    | 0.265     |
| Chill                          | 41 (16.9) | 36 (17.7) | 5 (12.5)  | 0.419     |
| Conjunctival congestion        | 1 (0.4)   | 1 (0.5)   | 0         | 0.835     |
| Dizziness                      | 45 (18.5) | 37 (18.2) | 8 (20)    | 0.792     |

**Laboratory findings**

| Test                          | Count 1   | Count 2   | Count 3   | Count 4   |
|-------------------------------|-----------|-----------|-----------|-----------|
| White blood cell count, \( \times 10^9 / L \) | 5 (2.1)   | 4.8       | 5.9 (2.8) | 0.006     |
| <10                            | 236 (97.1)| 199 (98)  | 37 (92.5) | 0.056     |
| ≥10                            | 7 (2.9)   | 4 (2)     | 3 (7.5)   |           |
| Lymphocyte count, \( \times 10^9 / L \) | 1.2 (0.6) | 1.2 (0.6) | 0.9 (0.4) | 0.07      |
| <1                            | 110 (45.3)| 87 (42.9) | 23 (57.5) | 0.089     |
| ≥1                            | 133 (54.7)| 116 (57.1)| 17 (42.5) |           |
| Monocyte count, \( \times 10^9 / L \) | 0.4 (0.2) | 0.4 (0.2) | 0.4 (0.3) | 0.02      |
| <0.5                          | 187 (77)  | 158 (77.8)| 29 (72.5) | 0.464     |
| ≥0.5                          | 56 (23)   | 45 (22.2) | 11 (27.5) |           |
| Platelet, \( \times 10^9 / L \) | 182 (66)  | 183 (66)  | 172 (67)  | 0.414     |
| <100                          | 19 (7.8)  | 15 (7.4)  | 4 (10)    | 0.574     |
| Value | Hemoglobin, g/L | D-dimer, mg/L | C-reactive protein, mg/L | α-Hydroxybutyrate dehydrogenase, U/L | Lactate dehydrogenase, U/L | Creatine kinase, U/L |
|-------|----------------|--------------|--------------------------|-------------------------------------|--------------------------|----------------------|
| ≥100  | 224 (92.2)     | 1 (2.2)      | 2.3 (3.1)                | 161 (161)                           | 197 (91)                 | 148                  |
|       | 188 (92.6)     | 0.8 (1.6)    | 2 (3)                    | 142 (57)                            | 185 (79)                 | 120                  |
|       | 36 (90)        | 2.1 (4)      | 3.6 (3.2)                | 247 (352)                           | 251 (119)                | 273 (636)            |
| <1    | 133 (26)       | 199 (81.9)   | 121 (49.8)               | 44 (18.1)                           | 122 (50.2)               | 122                  |
|       | 133 (28)       | 173 (85.2)   | 107 (52.7)               | 30 (14.8)                           | 96 (47.3)                | 96                   |
|       | 131 (19)       | 26 (65)      | 14 (35)                  | 14 (35)                             | 26 (65)                  | 14 (35)              |
| ≥1    | 44 (18.1)      | 122 (50.2)   | 122 (50.2)               | 161 (161)                           | 197 (91)                 | 148                  |
| <1    | 121 (49.8)     | 107 (52.7)   | 14 (35)                  | 44 (18.1)                           | 122 (50.2)               | 122                  |
| ≥1    | 122 (50.2)     | 96 (47.3)    | 96 (47.3)                | 161 (161)                           | 197 (91)                 | 148                  |
| <180  | 195 (80.2)     | 173 (85.2)   | 22 (55)                  | 195 (80.2)                          | 173 (85.2)               | 173                  |
| ≥180  | 48 (19.8)      | 30 (14.8)    | 18 (45)                  | 195 (80.2)                          | 173 (85.2)               | 173                  |
| <250  | 199 (81.9)     | 178 (87.7)   | 21 (52.5)                | 199 (81.9)                          | 178 (87.7)               | 178                  |
| ≥250  | 44 (18.1)      | 25 (12.3)    | 19 (47.5)                | 199 (81.9)                          | 178 (87.7)               | 178                  |
| Creatine kinase, U/L | 148     | 120   | 273 (636) | 148     | 120   | 273 (636) |

Page 14/20
| Measurement                        | <190       | ≥190       | 95% CI                         | p-value |
|-----------------------------------|------------|------------|--------------------------------|---------|
| Alanine aminotransferase, U/L     | 214 (88.1) | 29 (11.9)  | 30                 (75)        | 0.005   |
| Aspartate aminotransferase, U/L   | 184 (90.6) | 19 (9.4)   | 31                 (26)        | 0.662   |
| γ-Glutamyltransferase, U/L        | 30 (45)    | 30 (48)    | 31                 (26)        | 0.07    |
| Blood urea nitrogen, mmol/L       | 27 (22)    | 29 (29)    | 34                 (25)        | 0.744   |
| Creatinine, μmol/L                | 6.7 (30)   | 7.1 (28)   | 9.2                 (11)       | <0.001  |
| Procalcitonin, ng/mL              | 0.09 (0.18)| 0.16 (0.28)| 0.16                (0.28)     | 0.135   |
| Brain natriuretic peptide         | 420 (2587) | 69 (109)   | 1532                (5210)     | <0.001  |
| NLR                               | 3.9 (4.2)  | 3.7 (3.9)  | 10.6                (7.7)       | <0.001  |
| Comorbidities                     | <190       | ≥190       | 95% CI                         | p-value |
| Any                               | 97 (40.2)  | 70 (34.8)  | 27                 (67.5)       | <0.001  |
| Hypertension                      | 45 (18.5)  | 30 (14.8)  | 15                 (37.5)       | 0.001   |
| Condition                        | Count | Mean (SD) | Count | Mean (SD) | Count | Mean (SD) | p-value |
|---------------------------------|-------|-----------|-------|-----------|-------|-----------|---------|
| Diabetes                        | 24    | 18 (8.9)  | 6     | 15        |       |           | 0.235   |
| Hyperlipemia                    | 10    | 8 (3.9)   | 2     | 5         |       |           | 0.671   |
| Chronic obstructive pulmonary   | 10    | 5 (2.5)   | 5     | 12.5      |       |           | 0.003   |
| Chronic pulmonary disease       | 12    | 8 (3.9)   | 4     | 10        |       |           | 0.116   |
| Cerebrovascular disease         | 1     | 1 (0.5)   | 0     |           |       |           | 0.036   |
| Chronic kidney disease          | 10    | 4 (2)     | 6     | 15        |       |           | 0.002   |
| Fatty liver                     | 12    | 9 (4.5)   | 3     | 7.5       |       |           | 0.316   |
| Hepatitis                       | 6     | 3 (1.5)   | 3     | 7.5       |       |           | 0.058   |
| Malignancy                      | 9     | 8 (4)     | 1     | 2.5       |       |           | 0.656   |
| Surgery history                 | 34    | 27        | 7     | 17.5      |       |           | 0.484   |
| Imaging features                |       |           |       |           |       |           |         |
| Initial CT score, median (IQR)  | 3     | 3 (0-15)  | 3     | 1 (1-15)  |       |           | 0.112   |
| Maximum CT score, median (IQR)  | 8     | 7 (0-20)  | 14    | 3 (28)    |       |           | <0.001  |
| Others                          |       |           |       |           |       |           |         |
| Onset of symptoms to hospital,  | 4     | 4 (2-7)   | 4     | 2-7       |       |           | 0.733   |
| median (IQR), days              |       |           |       |           |       |           |         |
| Hospital stay, median (IQR), days| 19    | 18 (13-24)| 22    | 18.5-28.5|       |           | <0.001  |
| Time from illness onset to highest CT score, median (IQR), days | 10 | 9 (6-12) | 13 | 8-17.8 | <0.001 |
Data are mean (SD), median (IQR), n (%), or n/N (%). NLR, Neutrophil Lymphocyte Ratio; SD, standard deviation; OR, odds ratio; IQR, interquartile range.
**Table 2. Risk factors associated with deterioration**

| Characteristics | Univariable | Multivariable | P value | p value |
|-----------------|-------------|---------------|---------|---------|
|                 | OR (95% CI) | OR (95% CI)   |         |         |
| **Age, years**  |             |               |         |         |
| ≥60             | 2.84 (1.41- 5.72) | 1.48 (0.54- 4.05) | 0.003   | 0.444   |
| **Sex (vs. female)** | 2.00 (1.01- 3.97) | 0.85 (0.32- 2.78) | 0.048   | 0.918   |
| **Symptoms**    |             |               |         |         |
| Chest tightness | 3.01 (1.47- 6.16) | 0.85 (0.32- 2.78) | 0.003   | 0.918   |
| **Laboratory findings** |       |               |         |         |
| **White blood cell count, ×10^9/L** |         |               |         |         |
| <10             | 1 (ref)     |               |         |         |
| ≥10             | 1.03 (0.87- 18.77) |               | 0.075   |         |
| **Lymphocyte count, ×10^9/L** |         |               |         |         |
| <1              | 1 (ref)     |               |         |         |
| ≥1              | 0.55 (0.28- 1.10) |               | 0.092   |         |
| **Monocyte count, ×10^9/L** |         |               |         |         |
| <0.5            | 1 (ref)     |               |         |         |
| ≥0.5            | 1.33 (0.62- 2.87) |               | 0.47    |         |
| **D-dimer, mg/L** |         |               |         |         |
| <1              | 1 (ref)     |               |         |         |
| Metric                                      | Reference Range | Value | p-Value |
|---------------------------------------------|-----------------|-------|---------|
| C-reactive protein, mg/L                    | ≥1              | 3.11 (1.46-6.62) | 0.003   |
|                                             | <1              | 1 (ref) |         |
| α-hydroxybutyrate dehydrogenase, U/L        | ≥180            | 4.72 (2.27-9.83) | <0.001  |
|                                             | <180            | 1 (ref) |         |
| Lactate dehydrogenase, U/L                  | ≥250            | 6.44 (3.05-13.62) | <0.001  |
|                                             | <250            | 1 (ref) |         |
| Creatine kinase, U/L                        | ≥190            | 3.23 (1.37-7.61) | 0.007   |
|                                             | <190            | 1 (ref) | 1 (ref) |
| Creatinine, μmol/L                          | ≥97             | 4.09 (1.46-11.51) | 0.008   |
|                                             | <97             | 1 (ref) | 1 (ref) |
| NLR                                         |                 | 1.13 (1.04-1.23) | <0.001  |
| Comorbidities (vs no)                       | Any             | 3.89 (1.89-8.01) | <0.001  |
|                                             | Hypertension    | 3.46 (1.64-7.31) | 0.001   |
| Chronic obstructive pulmonary disease | 5.66 (1.56-20.56) | 0.008 | 9.06 | (1.30-63.36) |
|---------------------------------------|-------------------|-------|------|--------------|

**Imaging features**

| Initial CT score, median (IQR) | 1.07 (0.97-1.17) | 0.184 |
|---------------------------------|-----------------|-------|
| Maximum CT score, median (IQR)  | 1.40 (1.26-1.56) | <0.001 | 1.39 | (1.21-1.60) |

**Others**

| Onset of symptoms to hospital, median (IQR), days | 1.03 (0.94-1.13) | 0.507 |
| Hospital stay, median (IQR), days | 1.07 (1.03-1.12) | 0.002 |
| Time from illness onset to highest CT score, median (IQR), days | 1.15 (1.07-1.23) | <0.001 |

Data are mean (SD), median (IQR), n (%), or n/N (%). NLR, Neutrophil Lymphocyte Ratio; SD, standard deviation; OR, odds ratio; IQR, interquartile range; CI, confidence interval.